STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [Form 4] HAEMONETICS CORP Insider Trading Activity

Haemonetics (NYSE: HAE) VP granted 2,220 RSUs, 197 shares withheld for tax

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Haemonetics Corp VP and Chief Accounting Officer Maryanne Maunsell Farris received a grant of 2,220 restricted stock units, each representing one share of common stock vesting in three equal annual installments. In connection with RSU vesting, 197 shares were withheld to cover tax obligations, leaving her with 4,281 directly held shares, including unvested RSUs.

Positive

  • None.

Negative

  • None.
Insider Maunsell Farris Maryanne
Role VP, Chief Accounting Officer
Type Security Shares Price Value
Tax Withholding Common Stock 197 $56.29 $11K
Grant/Award Common Stock 2,220 $0.00 --
Holdings After Transaction: Common Stock — 4,281 shares (Direct, null)
Footnotes (1)
  1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
RSUs granted 2,220 shares Restricted stock units awarded on May 15, 2026
Grant price per share $0.00 per share Equity award with no cash exercise price
Shares withheld for taxes 197 shares Withheld in connection with RSU vesting
Tax withholding price $56.29 per share Value used for tax-withholding disposition
Shares after transactions 4,281 shares Direct holdings following RSU activity
Tax-withholding transactions 1 transaction, 197 shares Summary of F-code disposition
restricted stock units financial
"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
long-term incentive compensation plan financial
"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan."
vest financial
"The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maunsell Farris Maryanne
(Last)(First)(Middle)
125 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP, Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026F197(1)D$56.294,281(2)D
Common Stock05/15/2026A2,220(3)A(4)6,501(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. This number includes unvested RSUs previously reported.
3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
/s/ Thomas V. Powers, attorney-in-fact for Ms. Farris05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Haemonetics (HAE) executive Maryanne Maunsell Farris receive in this Form 4?

Maryanne Maunsell Farris received 2,220 restricted stock units as equity compensation. Each RSU represents a contingent right to one share of Haemonetics common stock, vesting in three equal annual installments under the company’s long-term incentive compensation plan.

How do the new RSUs for Haemonetics (HAE) vest for Maryanne Maunsell Farris?

The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. This schedule spreads the equity compensation over time, aligning a portion of the executive’s compensation with multi-year service and company performance.

Why were 197 Haemonetics (HAE) shares disposed of in this filing?

The 197 shares were withheld to satisfy tax obligations triggered by RSU vesting, not sold in the open market. This tax-withholding disposition is a routine mechanism where the issuer retains shares instead of the executive paying cash taxes directly.

What is Maryanne Maunsell Farris’s direct Haemonetics (HAE) shareholding after these transactions?

After the RSU grant and tax withholding, she directly holds 4,281 shares of Haemonetics common stock. This figure includes unvested RSUs previously reported, reflecting both currently owned shares and contingent rights that vest over time.

At what price were the Haemonetics (HAE) tax-withheld shares valued?

The 197 shares withheld for tax obligations were valued at $56.29 per share. This per-share value is used solely for tax calculation purposes when settling obligations arising from the vesting of restricted stock units granted to the executive.